Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT04013048 Completed - Solid Tumor Clinical Trials

Study to Evaluate the Mass Balance and Biotransformation of [14C]-Fluzoparib in Chinese Patients With Solid Tumor

Start date: July 8, 2019
Phase: Phase 1
Study type: Interventional

Study to Evaluate the Mass Balance and Biotransformation of Single Dose [14C]-FZPL in Chinese Patients with Solid Tumor

NCT ID: NCT04011293 Recruiting - Clinical trials for Relapsed or Refractory Hematological Malignancies

A Clinical Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Injection (CNCT19) in the Treatment of Cluster of Differentiation 19 (CD19) Positive Relapsed or Refractory B Cell Malignancies

Start date: July 2019
Phase: Early Phase 1
Study type: Interventional

This is a single arm, open-label, single center study to determine the safety and efficacy of CNCT19 in adult patients with Relapsed or Refractory B cell Malignancies.

NCT ID: NCT04010071 Recruiting - Clinical trials for Biliary Tract Neoplasms

Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors

Start date: May 1, 2020
Phase: Phase 2
Study type: Interventional

The investigators design a phase II clinical study to explore the efficacy and safety of axitinib plus toripalimab as a second-line treatment in patients with hepatobiliary malignant tumors and to analyze potential biomarkers of therapeutic response.

NCT ID: NCT04009460 Terminated - Neoplasms Clinical Trials

A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Solid Tumors

Start date: June 28, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerance and Dose-Limiting Toxicity (DLT) of recombinant humanized PD-L1/4-1BB bispecific antibody (ES101) in patients with advanced solid tumors.

NCT ID: NCT04008797 Recruiting - Neoplasms Clinical Trials

A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor

Start date: July 11, 2019
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to assess the safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with other anticancer drug(s).

NCT ID: NCT04008524 Available - Clinical trials for Relapsed and Refractory Hematological Malignancies

A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies

Start date: n/a
Phase:
Study type: Expanded Access

This project is intended to provide CAR-T cell therapy products for patients with severely life-threatening relapsed and refractory hematological malignancies. These patients have been previously treated sufficiently, currently have no other treatment methods available, and do not meet the inclusion criteria of other clinical trial projects in the process of subject recruitment or meet their exclusion criteria. This project is designed to meet the urgent clinical needs of individual patients.

NCT ID: NCT04008394 Recruiting - Hodgkin Lymphoma Clinical Trials

Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies

Start date: July 3, 2019
Phase: Phase 1
Study type: Interventional

The overall purpose of this study is to explore the safety and therapeutic effect of CD30-targeted chimeric antigen receptor T(CAR-T) cells in the treatment of Refractory/Relapsed lymphocyte malignancies.

NCT ID: NCT04008082 Completed - Neoplasms Clinical Trials

A Study of Overall Survival in Participants With Unresectable Hepatocellular Carcinoma

Start date: May 14, 2019
Phase:
Study type: Observational

The primary purpose of this study to continue follow-up of participants enrolled in the study E7080-M081-504 (NCT03663114) of lenvima capsules and to evaluate the overall survival of participants with hepatocellular carcinoma.

NCT ID: NCT04007783 Recruiting - Quality of Life Clinical Trials

Validation of the O-bridge Protocol: a Prospective, Multicenter Trial

Start date: March 4, 2017
Phase:
Study type: Observational

Surgical reconstruction to restore oral function and aesthetics after major ablative surgery in the oral cavity forms a challenge to maxillofacial surgeons, and greatly impacts patient' quality of life (QOL). The "Oncological-bridge (O-bridge®)" protocol, which offers (immediate/delayed) fixed prosthetic rehabilitation in a minimum of sessions and a strongly reduced two-week treatment time.

NCT ID: NCT04007744 Recruiting - Metastatic Melanoma Clinical Trials

Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors

Start date: February 13, 2020
Phase: Phase 1
Study type: Interventional

This phase I trial studies the best dose of sonidegib when given together with pembrolizumab and to see how well they work in treating patients with solid tumor that has spread to other places in the body (advanced). Sonidegib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving sonidegib and pembrolizumab may work better than standard treatment in treating patients with advanced solid tumors.